GSA Capital Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-60,870
| Closed | -$1.09M | – | 1988 |
|
|
2017
Q4 | $1.09M | Sell |
60,870
-51,300
| -46% | -$632K | 0.07% | 546 |
|
|
2017
Q3 | $1.32M | Buy |
112,170
+96,937
| +636% | +$1.09M | 0.09% | 343 |
|
|
2017
Q2 | $160K | Sell |
15,233
-258,800
| -94% | -$2.64M | 0.01% | 1542 |
|
|
2017
Q1 | $3.01M | Buy |
274,033
+248,128
| +958% | +$2.88M | 0.16% | 104 |
|
|
2016
Q4 | $351K | Sell |
25,905
-50,739
| -66% | -$708K | 0.02% | 1233 |
|
|
2016
Q3 | $943K | Sell |
76,644
-5,896
| -7% | -$69.5K | 0.05% | 647 |
|
|
2016
Q2 | $905K | Sell |
82,540
-99,258
| -55% | -$1.11M | 0.05% | 700 |
|
|
2016
Q1 | $1.99M | Sell |
181,798
-38,083
| -17% | -$481K | 0.13% | 184 |
|
|
2015
Q4 | $3.8M | Buy |
219,881
+17,172
| +8% | +$308K | 0.19% | 73 |
|
|
2015
Q3 | $4.03M | Sell |
202,709
-25,435
| -11% | -$583K | 0.2% | 64 |
|
|
2015
Q2 | $3.75M | Buy |
228,144
+116,734
| +105% | +$2.02M | 0.14% | 107 |
|
|
2015
Q1 | $1.73M | Buy |
111,410
+87,492
| +366% | +$1.36M | 0.07% | 438 |
|
|
2014
Q4 | $342K | Buy |
+23,918
| New | +$253K | 0.02% | 1185 |
|
|
2014
Q2 | – | Sell |
-28,526
| Closed | -$204K | – | 2052 |
|
|
2014
Q1 | $204K | Buy |
+28,526
| New | +$244K | 0.01% | 1379 |
|
|
2013
Q4 | – | Sell |
-28,726
| Closed | -$179K | – | 1856 |
|
|
2013
Q3 | $179K | Buy |
28,726
+15,007
| +109% | +$93.7K | 0.01% | 1415 |
|
|
2013
Q2 | $90K | Buy |
+13,719
| New | +$109K | 0.01% | 1208 |
|
Other funds holding SCMP
GSA Capital Partners's SCMP Position: Q1 2018 in Review
GSA Capital Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 60,870 shares — an estimated $1.09M sold.
GSA Capital Partners first reported a position in SCMP in Q2 2013 and held it in 16 quarters. The position peaked at $4.03M in Q3 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- GSA Capital Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
- GSA Capital Partners sold 60,870 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.09M.
- GSA Capital Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 16 quarters.
- GSA Capital Partners's Sucampo Pharmaceuticals, Inc. position peaked at $4.03M in Q3 2015.
- 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.
Based on GSA Capital Partners's 13F filing for Q1 2018, filed 11 May 2018.